One thing is for certain: in 2026, a top crypto presale is not decided by hype, but by real utility and real demand. That question keeps coming up as crypto ...

Every cycle has that one moment that splits winners from watchers. That’s the moment a project stops being “one to monitor” and becomes the one people wish ...

The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a public listing that could see proceeds of around $210m. The cancer treatment-focused biotech ...